News Releases

Date	Title and Summary	View
Mar 18, 2020	Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis
Mar 17, 2020	Johnson & Johnson to Host Investor Conference Call on First-Quarter Results NEW BRUNSWICK, N.J. , March 17, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14 th to review first-quarter results. Joseph J. Wolk , Executive Vice President, Chief Financial Officer and Christopher
Mar 13, 2020	Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development Research well underway as Janssen scientists collaborate with leading virology laboratory led by Dan Barouch, M.D., Ph.D. NEW BRUNSWICK, N.J. , March 13, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies have entered a collaboration with
Mar 10, 2020	Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
Mar 04, 2020	Janssen Submits European Marketing Authorisation Application for Ponesimod for Treatment of Adults with Relapsing Multiple Sclerosis
Mar 02, 2020	European Medicines Agency Grants PRIME and Advanced Therapy Medicinal Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosa
Feb 26, 2020	Johnson & Johnson to Participate in Barclays Global Healthcare Conference NEW BRUNSWICK, N.J. , Feb. 26, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference on Wednesday, March 11 th , at the Loews Miami Beach Hotel , Miami Beach , FL. Ciro Romer , Company Group Chairman, Medical Devices North America will
Feb 18, 2020	Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments Janssen strengthens collaboration with Biomedical Advanced Research and Development Authority (BARDA) in an effort to stem the threat of the global COVID-19 outbreak NEW BRUNSWICK, N.J. , Feb. 18, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical
Feb 12, 2020	Johnson & Johnson to Participate in the 9th Annual SVB Leerink Global Healthcare Conference NEW BRUNSWICK, N.J. , Feb. 12, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 9 th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26 th , at Lotte New York Palace, NY. Ashley McEvoy , Executive Vice President, Worldwide Chairman, Medical Devices will
Feb 11, 2020	Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine Janssen joins forces with Biomedical Advanced Research and Development Authority (BARDA) to protect communities against threat of a global COVID-19 pandemic NEW BRUNSWICK, N.J. , Feb. 11, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies